Hospital incidence and medical costs of polycythemia vera in Spain: a retrospective database analysis
- 21 February 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 22 (6) , 1-6
Abstract
Polycythemia vera (PV) is one of the most common chronic myeloproliferative neoplasms, yet, little data is available on the epidemiology of PV in Spain and the costs of its management. This study aimed to evaluate the hospital incidence and mortality rate of PV in Spain, and to estimate hospital medical costs. Hospital admission records of patients with PV registered between 2005 and 2019 were obtained from a Spanish hospital discharge database and analyzed in a retrospective multicenter study. Admission files of 490 patients were reviewed. Median age was 74 years; patients presented numerous conditions associated to age, namely hypertension, diabetes or anemia. Hospital mortality rate was associated to pulmonary heart disease, respiratory conditions and kidney disease. Most of the files analyzed corresponded to inpatient admissions; hospital incidence decreased over the study period in patients over 60 years. Median admission cost was €5580, increasing in patients deceased during the hospitalization. Admission cost increased significantly between 2006 and 2011. This study provides an evaluation of hospital management and costs of PV in Spain. Future studies should focus on the revision of disease management in the country and measuring total medical costs, which could be higher than global estimations.Keywords
This publication has 20 references indexed in Scilit:
- Polycythemia vera treatment algorithm 2018Blood Cancer Journal, 2018
- Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia VeraJournal of Managed Care & Specialty Pharmacy, 2018
- What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?Hematology-American Society Hematology Education Program, 2017
- How We Identify and Manage Patients with Inadequately Controlled Polycythemia VeraCurrent Hematologic Malignancy Reports, 2016
- Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsBlood Cancer Journal, 2015
- Novel and emerging therapies for the treatment of polycythemia veraExpert Review of Hematology, 2014
- Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment optionsAnnals of Hematology, 2014
- Epidemiology of MPN: What Do We Know?Current Hematologic Malignancy Reports, 2014
- Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health planLeukemia & Lymphoma, 2014
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyLeukemia, 2013